🩺 ASCVD Risk Stratification & LDL-C Target (China Lipid Guideline 2023)
UseSet an individualised LDL-C goal and lipid-lowering plan once risk stratum is known.
Loading calculator…
SourceJoint Committee for Guideline Revision. China Guideline for Lipid Management (2023). Chin J Cardiol…
Runs locally in your browser (no PHI uploaded). For licensed clinicians — not a substitute for clinical judgement.
Stored on this device for revisit reminders
This-shift next steps
After scoring: open the scene pack, peer scores, and the matching pathway. Local reference — no HIS write.
- Who it is for
- Adults using the Chinese population model for 10-year risk and a lipid-intensity band.
- Who it is not for
- US PCE is not the main door for ASCVD in China. Pregnancy does not enter statin intensity; contraindication or caution only.
- Formula and variables
- The main door is China-PAR, the equation already on this page: sex, age, region, urban or rural, waist, treated or untreated systolic pressure, total cholesterol, HDL cholesterol, smoking, diabetes, family history, and the rest. Coefficients stay as on this page and are not changed. This equation is not the risk-factor counting flowchart. Until that crosswalk is pinned, the two cannot be swapped automatically.
- Result → next step
- Give the risk band first. The main door for ASCVD in China is China-PAR, not US PCE. An LDL-cholesterol target band may open the existing target page, but a China-PAR percent must not be dropped straight into a flowchart cell. Intensity band or defer only. No numeric dose. Pregnancy uses the pregnancy-medication page for contraindication or caution only.China-PAR main door →
- Guideline
- China blood lipid guideline 2023
Scene next step
📋ASCVD / China-PAROpen scene pack →Related scores
Matching pathway
🧭htn_emergencyOpen pathway →Score + version; reference only — not a substitute for care · no HIS write
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
Methodology · worked example, guidelines & full notes
Clinical takeaway
LDL-C is the primary lipid target; non-HDL-C is the secondary target.
When to use
Set an individualised LDL-C goal and lipid-lowering plan once risk stratum is known.
How it works
LDL-C targets: extreme-high < 1.4, very-high < 1.8, high/intermediate < 2.6, low < 3.4 mmol/L (secondary-prevention strata also require ≥ 50% reduction). Non-HDL-C target = LDL-C target + 0.8 mmol/L.
Key points
- LDL-C is the primary lipid target; non-HDL-C is the secondary target.
- Stepwise therapy: moderate-intensity statin → add ezetimibe → add a PCSK9 inhibitor if still not at goal.
- For hard-to-classify intermediate risk, risk-enhancing factors (high Lp(a), LV hypertrophy, premature family history) favour treating as high risk.
- Targets are closely aligned with the ESC 2021 dyslipidaemia guideline.
References
- [Guideline / primary source]Joint Committee for Guideline Revision. China Guideline for Lipid Management (2023). Chin J Cardiol 2023
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Established ASCVD (CHD / ischaemic stroke / PAD etc.)? | Yes (secondary prevention) |
|---|---|
| [Secondary] number of severe ASCVD events (ACS < 1 yr / old MI / ischaemic stroke / symptomatic PAD) | 1 |
| [Secondary] number of high-risk factors (premature CHD / FH or LDL ≥ 4.9 / prior CABG-PCI / diabetes / hypertension / CKD 3–4 / smoking / recurrence with LDL ≤ 1.8) | 1 |
| [Primary] meets direct high-risk (LDL ≥ 4.9 or TC ≥ 7.2 / diabetes & age ≥ 40 / CKD stage 3–4 — any)? | Yes |
| [Primary] if not direct high-risk: 10-year ASCVD risk assessment result | Intermediate |
→LDL-C target< 1.8 mmol/L
- Risk stratum：Very-high risk
- Reduction required：≥ 50% reduction from baseline
- Non-HDL-C target：< 2.6 mmol/L
Verification & sources · governance
FAQ
Frequently asked questions
- What are the limits and cautions when using ASCVD Risk Stratification & LDL-C Target (China Lipid Guideline 2023)?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- Does ASCVD Risk Stratification & LDL-C Target (China Lipid Guideline 2023) upload patient data? Where is it calculated?
- Calculation runs locally in the browser; inputs and results are not uploaded. For licensed clinicians only; interpret with history, investigations and local protocols — not a diagnosis or prescription.
- How is ASCVD Risk Stratification & LDL-C Target (China Lipid Guideline 2023) calculated in practice? Can you show a worked example?
- Inputs: Established ASCVD (CHD / ischaemic stroke / PAD etc.)? Yes (secondary prevention), [Secondary] number of severe ASCVD events (ACS < 1 yr / old MI / ischaemic stroke / symptomatic PAD) 1, [Secondary] number of high-risk factors (premature CHD / FH or LDL ≥ 4.9 / prior CABG-PCI / diabetes / hypertension / CKD 3–4 / smoking / recurrence with LDL ≤ 1.8) 1, [Primary] meets direct high-risk (LDL ≥ 4.9 or TC ≥ 7.2 / diabetes & age ≥ 40 / CKD stage 3–4 — any)? Yes, [Primary] if not direct high-risk: 10-year ASCVD risk assessment result Intermediate → Result: LDL-C target < 1.8 mmol/L（Risk stratum: Very-high risk, Reduction required: ≥ 50% reduction from baseline, Non-HDL-C target: < 2.6 mmol/L）